Case Report: Complete pathologic response to neoadjuvant immunotherapy-chemotherapy in a patient with RET fusion-positive non-small cell lung cancer
Authors:
- Yan WangYWYan Wang
- Yan ZhangYZYan Zhang
- Chenlei CaiCCChenlei Cai
- Xinyu LiuXLXinyu Liu
- Shengxiang RenSRShengxiang Ren
- Songwen ZhouSZSongwen Zhou
Open Access
- 29 January 2026
- journal article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16
Abstract
RET fusions are rare, and occur in 1%-2% of all non-small cell lung cancer (NSCLC) patients. While neoadjuvant immunotherapy-chemotherapy has demonstrated significant benefit for resectable NSCLC, data remain limited for oncogene-positive NSCLC, particularly for rare alterations like RET fusions. Herein, we present a clinical case of a patient with stage IIIA RET fusion-positive adenocarcinoma who received neoadjuvant nivolumab immunotherapy combined with nab-paclitaxel and carboplatin chemotherapy followed by surgery. The postoperative pathologic results revealed pathological complete response (pCR) and no residual viable tumor cells were observed in lymph nodes. This case validates the clinical activity of immunotherapy-chemotherapy in the neoadjuvant setting, providing a foundation for continued exploration in the treatment of early-stage RET fusion-positive NSCLC.Keywords
This publication has 22 references indexed in Scilit:
- Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non–Small Cell Lung CancerJAMA Oncology, 2025
- Rearranged during transfection (RET) lung cancer – Update on targeted therapiesLung Cancer, 2025
- Neoadjuvant therapy in non-small cell lung cancerCritical Reviews in Oncology/Hematology, 2023
- Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trialSignal Transduction and Targeted Therapy, 2023
- Neoadjuvant Targeted Therapy in Non–Small Cell Lung Cancer and Its Impact on Surgical OutcomesAnnals of Thoracic Surgery Short Reports, 2022
- Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung CancerNew England Journal of Medicine, 2022
- Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 studyThe Lancet Oncology, 2021
- Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trialThe Lancet Oncology, 2020
- RET fusions in solid tumorsCancer Treatment Reviews, 2019
- Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapesNature Reviews Clinical Oncology, 2017